This work aims to investigate the effects of tetramethylpyrazine (TMP) on the proliferation, migration, and invasion of glioma cells and to analyze the regulation mechanism of TMP on the long noncoding RNA UBL7-AS1/miR-144-3p pathway. Glioma cell line and normal astrocytes were collected. The expression of UBL7-AS1 was detected by real-time PCR. The glioma cells were overexpressed with UBL7-AS1. CCK-8 and Transwell assays were used to detect cell proliferation and cell invasion ability, respectively. Bioinformatics was adopted to predict the possible regulatory mechanisms of UBL7-AS1. The dual luciferase reporter gene was applied to verify the regulatory effect of RNA UBL7-AS1 with miR-144-3p. TMP inhibited the proliferation and invasion of glioma cells. UBL7-AS1 was highly expressed in glioma tissues and cells. The overexpression of UBL7-AS1 promotes the cell proliferation and invasion of glioma. UBL7-AS1 can act as a sponge for miR-144-3p in glioma cells. The overexpression of UBL7-AS1 can reverse the inhibition of TMP on proliferation, migration, and invasion of glioma cells. TMP inhibits the proliferation, migration, and invasion of glioma cells by regulating the UBL7-AS1/miR-144-3p pathway.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423964 | PMC |
| http://dx.doi.org/10.1155/2022/5261285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of TIM-3 in Glioblastoma Progression.
Cells
February 2025
Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Several immunoregulatory or immune checkpoint receptors including T cell immunoglobulin and mucin domain 3 (TIM-3) have been implicated in glioblastoma progression. Rigorous investigation over the last decade has elucidated TIM-3 as a key player in inhibiting immune cell activation and several key associated molecules have been identified both upstream and downstream that mediate immune cell dysfunction mechanistically. However, despite several reviews being published on other immune checkpoint molecules such as PD-1 and CTLA-4 in the glioblastoma setting, no such extensive review exists that specifically focuses on the role of TIM-3 in glioblastoma progression and immunosuppression.
View Article and Find Full Text PDFIndividual Brain Tumor Invasion Mapping Based on Diffusion Kurtosis Imaging.
Sovrem Tekhnologii Med
March 2025
MD, DSc, Professor, Academician of the Russian Academy of Sciences, Director; N.N. Burdenko National Medical Research Center of Neurosurgery of the Ministry of Health of the Russian Federation, 16, 4th Tverskaya-Yamskaya St., Moscow, 125047, Russia.
Unlabelled: is to develop and implement an algorithm for image analysis in brain tumors (glioblastoma and metastasis) based on diffusion kurtosis MRI images (DKI) for the assessment of anisotropic changes in brain tissues in the directions from the tumor to the intact (as shown by the standard MRI data) white matter, which will enable generating individual tumor invasion maps.
Materials And Methods: A healthy volunteer and two patients (one with glioblastoma and the other with a single metastasis of small cell lung cancer) were examined by DKI obtaining 12 parametric kurtosis maps for each participant.
Results: During the investigation, we have developed an algorithm of DKI analysis and plotting the profile of tissue parameters in the direction from the tumor towards the unaffected white matter according to the data of standard MRI.
Efficacy Evaluation of "Enhanced" Natural Killers with and Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients.
Sovrem Tekhnologii Med
March 2025
MD, PhD, Senior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Head of the Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Senior Researcher, Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia.
Unlabelled: One of the alternative approaches to glioblastoma treatment is cellular immunotherapy based on natural killer cells (NK cells). To enhance their cytotoxic effect on tumor cells, new NK cell lines are being created using genetic engineering techniques. was to evaluate the impact efficacy of "enhanced" NK cells on early metabolic rearrangements and the viability of glioblastoma cells in a patient using a tumor spheroid model.
View Article and Find Full Text PDFMigration of Regulatory T Cells to the Peritumor Microenvironment of Experimental Glioblastoma.
Sovrem Tekhnologii Med
March 2025
MD, PhD, Head of the Laboratory of Solid Tumor Immunotherapy; Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency of Russia, 1, Bldg. 10, Ostrovityanova St., Moscow, 117513, Russia; Senior Researcher, Laboratory of Cell Technologies; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical Biological Agency of Russia, 28 Orekhovy Blvd., Moscow, 115682, Russia; Senior Researcher, Laboratory of Molecular Regeneration Mechanisms; Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 32 Vavilov St., Moscow, 119991, Russia.
Unlabelled: Glioblastoma is the most aggressive primary brain tumor with poor prognosis characterized by resistance to standard treatments and immune evasion. Regulatory T lymphocytes (Tregs) play a key role in immune suppression in the tumor microenvironment and can be used as targets for malignant gliomas therapy. is to study migration of Tregs to the tumor site in the process of dynamic glioblastoma growth on the transgenic C57Bl/6-FoxP3-eGFP mouse line.
View Article and Find Full Text PDFLocoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial.
Neuro Oncol
March 2025
Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle Washington.
Background: Relapsed/refractory pediatric CNS tumors have a poor prognosis. EGFR is commonly overexpressed, but EGFRvIII mutations are uncommon. To target these tumors, we used chimeric antigen receptor (CAR) T cells with a binder based on mAb806 which recognizes ectopically expressed wild-type EGFR and EGFRvIII.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!